Atrion (NASDAQ:ATRI) Sees Strong Trading Volume

Atrion Co. (NASDAQ:ATRI) shares saw strong trading volume on Monday . 14,391 shares changed hands during mid-day trading, a decline of 23% from the previous session’s volume of 18,792 shares.The stock last traded at $418.86 and had previously closed at $414.95.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Atrion from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st.

Atrion Stock Down 1.7 %

The firm’s 50 day simple moving average is $415.83 and its two-hundred day simple moving average is $366.56. The stock has a market cap of $721.92 million, a P/E ratio of 37.19 and a beta of 0.62.

Atrion (NASDAQ:ATRI) last released its earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%. The firm had revenue of $43.58 million during the quarter.

Atrion Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 15th were given a dividend of $2.20 per share. The ex-dividend date was Thursday, March 14th. This represents a $8.80 annualized dividend and a dividend yield of 2.15%. Atrion’s dividend payout ratio is currently 79.78%.

Hedge Funds Weigh In On Atrion

Institutional investors have recently modified their holdings of the company. Citizens Financial Group Inc. RI bought a new position in shares of Atrion during the fourth quarter worth about $1,114,000. Charles Schwab Investment Management Inc. lifted its holdings in Atrion by 2.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 10,385 shares of the medical instruments supplier’s stock worth $4,291,000 after purchasing an additional 243 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Atrion by 592.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 231 shares during the period. Bank of New York Mellon Corp lifted its holdings in Atrion by 2.0% in the third quarter. Bank of New York Mellon Corp now owns 10,006 shares of the medical instruments supplier’s stock worth $4,134,000 after purchasing an additional 194 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in Atrion in the third quarter worth about $208,000. Institutional investors own 66.19% of the company’s stock.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.